Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
- Resource Type
- Article
- Source
- In
Cancer Letters 2008 265(2):307-317 - Subject
- Language
- ISSN
- 0304-3835